🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis

Recruitingn/aAges 18 Years - 75 YearsAllAbbVie
NCT06764693 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Psoriatic arthritis (PsA) is a type of arthritis (swelling and stiffness in the joints) that is frequently seen in trial participants who also have the skin condition psoriasis. It is caused by an overactive immune system where the body attacks healthy tissue by mistake. This study aims to describe the long term usage and effectiveness with risankizumab (RZB) relative to other advanced therapeutic options for the management of PsA in daily clinical practice. Risankizumab is an approved drug for the treatment of psoriatic arthritis. The study will not be conducted in the United States, however it will be conducted in approximately 15 countries and include at least 900 and up to 1200 participants with a 2 to1 ratio of participant allocation between participants receiving risankizumab and participants receiving other advanced therapeutic agents. The therapy is prescribed in the usual mann

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Participant with a clinical diagnosis of psoriatic arthritis (PsA) with symptom onset at least 6 months prior to the Screening visit and fulfillment of ClASsification for Psoriatic ARthritis (CASPAR) at Baseline visit to confirm that the participant has active disease. * Participant must have demonstrated an inadequate response to at least 1 Disease-modifying antirheumatic drug (DMARD) (with max 50% Biologic DMARD-Inadequate Response); alternatively, participant must have demonstrated an intolerance to or contraindication for csDMARDs as determined by the investigator. Exclusion Criteria: \- Participants demonstrated an inadequate response to three or more bDMARDs/targeted synthetic DMARDs (tsDMARDs).
💊

What it tests

  • Not listed
📍

Where

132 sites
Cer Instituto Médico /ID# 274445
Quilmes, Argentina
Instituto Medico de Alta Complejidad San Isidro S.A. /ID# 274417
San Isidro, Argentina
Instituto Médico Río Cuarto /ID# 274421
Río Cuarto, Argentina
Landesklinikum Stockerau /ID# 275618
Stockerau, Austria
Rheuma-Zentrum Wien-Oberlaa GmbH /ID# 275617
Vienna, Austria
Medizinische Universitaet Graz /ID# 273765
Graz, Austria
Krankenhaus Der Barmherzigen Brueder Graz /ID# 273764
Graz, Austria
Universite Libre de Bruxelles - Hopital Erasme /ID# 272763
Anderlecht, Belgium

…and 124 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy